WILLFACT

This brand name is authorized in Austria, Estonia, Spain, Lithuania, Poland, United Kingdom

Active ingredients

The drug WILLFACT contains one active pharmaceutical ingredient (API):

1 Von Willebrand factor from human plasma
UNII ZE22NE22F1 - VON WILLEBRAND FACTOR HUMAN

Administration of von Willebrand factor allows correction of the haemostatic abnormalities exhibited by patients who suffer from von Willebrand factor deficiency.

Read about Von Willebrand factor

Medication package inserts

Below package inserts are available for further reading:

Title Information Source Document Type  
WILLFACT Powder and solvent for solution for injection Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
B02BD10 Von Willebrand factor B Blood and blood forming organs → B02 Antihemorrhagics → B02B Vitamin K and other hemostatics → B02BD Blood coagulation factors
Discover more medicines within B02BD10

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: EE Ravimiamet Identifier(s): 1461978, 1632743, 1632956
Country: ES Centro de información online de medicamentos de la AEMPS Identifier(s): 73760
Country: GB Medicines & Healthcare Products Regulatory Agency Identifier(s): 245562
Country: LT Valstybinė vaistų kontrolės tarnyba Identifier(s): 1053690, 1071938, 1071939
Country: PL Rejestru Produktów Leczniczych Identifier(s): 100247921, 100340508, 100340514

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.